

Study Subjects

The study was approved by the Institutional Review Board of the College of Medicine, King Saud University, Riyadh, Saudi Arabia (registration no. E-18-3075). Recruited patients were asked to sign a written informed consent form before enrolling. Twenty patients who were diagnosed with T2DM were referred to the King Khaled University Hospital's (KKUH), Obesity Research Center, where this study took place. Patients were treated with an appropriate dose of Liraglutide for three months. Samples were taken pre-treatment and post-treatment. Note: the T2DM participants were on other medications including insulin and metformin beside the Liraglutide treatment.